SONIC HEALTHCARE LIMITED (SHL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SHL - SONIC HEALTHCARE LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Sonic Healthcare is one of the world's largest medical diagnostics companies, providing laboratory and imaging services to medical practitioners, hospitals, community health services, and their collective patients. It was first listed in 1987.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$41.49

23 Sep
2021

-0.230

OPEN

$41.72

-0.55%

HIGH

$41.84

1,158,031

LOW

$41.43

TARGET
$43.83 5.6% upside
Franking for last dividend paid out: 65%
OTHER COMPANIES IN THE SAME SECTOR
EBO . SLA . CAJ . GXL . HSO . MPL . MVF . NHF . HLS . RHC . VRT . M7T . HLA . PSQ . SIL . PKS . ONT . DOC . NVL . AHX . ALC . ACL .
FNARENA'S MARKET CONSENSUS FORECASTS
SHL: 1
Title FY20
Actual
FY21
Actual
FY22
Forecast
FY23
Forecast
EPS (cps) xxx 275.5 227.5 xxx
DPS (cps) xxx 91.0 97.6 xxx
EPS Growth xxx 100.0% - 17.4% xxx
DPS Growth xxx 7.1% 7.2% xxx
PE Ratio xxx N/A 17.8 xxx
Dividend Yield xxx N/A 2.4% xxx
Div Pay Ratio(%) xxx 33.0% 42.9% xxx

Dividend yield today if purchased 3 years ago: 3.61%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

2.25

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 07/09 - 55c (65%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx275.5
DPS All xxxxxxxxxxxxxxx91.0
Sales/Revenue xxxxxxxxxxxxxxx9,126.7 M
Book Value Per Share xxxxxxxxxxxxxxx1,336.0
Net Operating Cash Flow xxxxxxxxxxxxxxx2,042.8 M
Net Profit Margin xxxxxxxxxxxxxxx14.41 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Assets xxxxxxxxxxxxxxx10.78 %
Return on Equity xxxxxxxxxxxxxxx21.99 %
Return on Total Capital xxxxxxxxxxxxxxx22.91 %
Capex xxxxxxxxxxxxxxx363.2 M
Capex % of Sales xxxxxxxxxxxxxxx3.98 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx1,264.1 M

Return on Assets

Return on Equity

Return on Total Capital

Capex

Capex % of Sales

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Credit Suisse

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

24/08/2021

1

Add

$45.98

10.82%

FY21 underlying results were in-line with consensus expectations, with covid testing driving upside across all laboratory businesses. There's considered a strong outlook, given increased delta variant testing and emerging related activities along with a solid base business.

The base testing business (ex-covid) continues to demonstrate resilience, while Imaging posted double digit growth and market share gains offsetting modest sales softness in the pandemic-impacted Clinical Services, explains the analyst.

While covid uncertainty is likely to continue to cloud the near and medium term, Morgans believes there will likely be continued organic growth and retains its Add rating. The target price increases to $45.98 from $36.15.

FORECAST
Morgans forecasts a full year FY22 dividend of 95.00 cents and EPS of 211.00 cents.
Morgans forecasts a full year FY23 dividend of 99.00 cents and EPS of 152.00 cents.

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

SHL STOCK CHART